pyrotinib: Clinical Trials

99 trials of pyrotinib, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

48 unknown, 24 recruiting, 16 not yet recruiting, 6 active not recruiting. 99 Phase 2, 9 Phase 1, 3 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 299Unknown 48, Recruiting 24, Not yet recruiting 16, Active not recruiting 6, Completed 4, Terminated 1
Phase 19Unknown 5, Recruiting 3, Not yet recruiting 1
Phase 33Active not recruiting 1, Not yet recruiting 1, Recruiting 1

Follow pyrotinib: new trials by email Literature Review of pyrotinib trials Research Report on pyrotinib

Trials (filtered) newest first · largest first

All 99 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Study of RC48-ADC Combined With Pyrotinib For Treatment of Local Advanced or Metastasis NSCLC With HER2 Mutation
RC48-ADC, Pyrotinib - Non-small Cell Lung Cancer
Phase 1 / Phase 2Not yet recruitingRemeGen Co., Ltd.262027-12-012026-09-22
A Phase II Study of Trastuzumab Deruxtecan (T-DXd) Plus Pyrotinib in HER2-Positive Advanced Breast Cancer After Progression on T-DXd
Trastuzumab Deruxtecan (T-DXd), Pyrotinib - Breast Cancer
Phase 2Not yet recruitingFujian Medical University282026-10-102026-09-23
Trastuzumab Rezetecan Followed by Pyrotinib, and Trastuzumab Combined With Capecitabine as First-line Treatment for Advanced HER2-positive Breast Cancer
Trastuzumab Rezetecan, Pyrotinib, trastuzumab - HER2 + Breast Cancer, Advanced Breast Cancer
Phase 2Not yet recruitingFujian Cancer Hospital502026-09-302026-08-14
Precision Medicine for Immunotherapy-Resistant Advanced Esophageal Cancer
Afatinib + Toripalimab, Dalpiciclib + Pyrotinib, Camrelizumab + Apatinib - Esophageal Squamous Cell Carcinoma
Phase 2 / Phase 3Not yet recruitingPeking University Cancer Hospital & Institute902026-07-012026-06-17
Dalpiciclib, Anti-HER2 Therapy, and Endocrine Therapy for Hormone-Receptor-Positive, HER2-Positive Metastatic Breast Cancer
Dalpiciclib, Trastuzumab (Herceptin), Pertuzumab - Advanced/Metastatic Breast Cancer, HER2-Positive Metastatic Breast Cancer
Phase 2RecruitingSun Yat-sen University572026-06-012026-05-28
SHR-A1811 vs Pyrotinib/Capecitabine in Trastuzumab-Resistant HER2+ Advanced Breast Cancer: A Randomized Study
SHR-A1811, Pyrotinib, Capecitabine - Breast Cancer, HER2-positive Breast Cancer
Phase 2Not yet recruitingPeking University Cancer Hospital & Institute1002026-03-312026-02-18
Neoadjuvant Trastuzumab Deruxtecan (SHR-A1811) + Pertuzumab in HER2+ Breast Cancer
Trastuzumab Deruxtecan, Pertuzumab, Taxane Chemotherapy - HER2 + Breast Cancer
Phase 2RecruitingShanghai Jiao Tong University School of Medicine502026-02-022026-02-06
Neoadjuvant Trastuzumab-rezetecan Plus Pertuzumab or Nab-Paclitaxel, Carboplatin, Trastuzumab, and Pyrotinib After Suboptimal Response to Neoadjuvant Dual HER2-Targeted Therapy Combined With Chemotherapy in HER2-Positive Early Breast Cancer
Nab paclitaxel, Carboplatin, Trastuzumab - HER2-positive Early Breast Cancer
Phase 2RecruitingSecond Affiliated Hospital, Zhejiang University, School of Medicine2002025-12-252026-01-21
SHR-A1811 Plus Pertuzumab as Neoadjuvant Therapy for Early or Locally Advanced HR-Positive HER2-Positive Breast Cancer: A Prospective, Open-Label, Phase II Study
SHR- A1811 - SHR-A1811, HER2-Postive Breast Cancer
Phase 2Not yet recruitingTianjin Medical University Cancer Institute and Hospital302025-12-202025-12-29
Maintenance Therapy in HER2-Positive Unresectable Locally Recurrent or Metastatic Breast Cancer: A Phase II Study
Trastuzumab rezetecan, Pyrotinib, Dalpiciclib - HER2-positive Breast Cancer
Phase 2Not yet recruitingFudan University2882025-09-102025-09-18
This Study Aims to Optimize Neoadjuvant Therapy for HER2-positive Breast Cancer by Implementing a Dynamic Monitoring-guided Treatment Strategy.
Patients will initially receive trastuzumab, pyrotinib, and albumin-bound paclitaxel. Those who do not achieve a radiological response after Cycle 2 will switch to SHR-A1811 (a HER2-targeted antibody, Patients will initially receive trastuzumab, pyrotinib, and nab-paclitaxel. Those who achieve a partial response (PR) or complete response (CR) after cycle 2 will continue on the same regimen. - HER2-positive Breast Cancer
Phase 2Not yet recruitingHebei Medical University Fourth Hospital302025-09-012025-08-05
SHR-A1811 Combine With Pyrotinib for Locally Advanced/Metastatic HER2 Positive Breast Cancer
SHR-A1811 4.0mg/kg, Pyrotinib 240mg, SHR-A1811 4.8mg/kg - Metastatic Breast Cancer With HER2 Positive
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences842025-08-302025-08-20
Continuous or Intermittent Pyrotinib for HER2-positive Advanced Breast Cancer
Pyrotinib - Advanced Breast Cancer
Phase 2RecruitingWenjin Yin1862025-08-282025-11-18
A Prospective, Open-label, Exploratory Basket Trial to Evaluate the Efficacy and Safety of Sintilimab Combined With Pyrotinib ± Chemotherapy in Patients With Advanced Digestive System Tumors
Sintilimab, Pyrotinib, Optional Chemotherapy - Advanced Digestive System Tumor
Phase 2Not yet recruitingTongji Hospital802025-08-152025-07-08
Oral Metronomic Capecitabine Combined With Pyrotinib in ADC-treated HER2-positive Metastatic Breast Cancer
Pyrotinib, Capecitabine - HER2-positive Breast Cancer, Metastatic Breast Cancer
Phase 2Not yet recruitingCancer Institute and Hospital, Chinese Academy of Medical Sciences1002025-06-302025-06-13
Entinostat Plus Pyrotinib and Endocrine Therapy in Advanced Triple-Positive Breast Cancer After Trastuzumab Failure
entinostat, Pyrotinib, endocrine therapy - Breast Cancer, HER2-positive Breast Cancer
Phase 1 / Phase 2RecruitingTianjin Medical University Cancer Institute and Hospital942025-06-232026-07-16
Study of SHR-A1811 Combined With Pyrotinib and Bevacizumab in Advanced Breast Cancer With Brain Metastasis
SHR-A1811, Bevacizumab, Pyrotinib - Breast Cancer Metastatic, Breast Cancer Brain Metastases
Phase 1 / Phase 2RecruitingFudan University742025-01-082025-02-06
Study of Precision Treatment for Rare Tumours in China Guided by PDO and NGS
Albumin-Bound Paclitaxel, Epirubicin, Gemcitabine - Rare Tumour
Phase 2Not yet recruitingPeking University Shenzhen Hospital2002025-01-012024-11-18
Neoadjuvant Chemotherapy Plus Pyrotinib and Trastuzumab for HER2-positive Breast Cancer (NEOTORCH-BREAST05)
pyrotinib and trastuzumab in combinition with neoadjuvant chemotherapy - HER2-positive Breast Cancer, Neoadjuvant Therapy
Phase 2RecruitingFirst Affiliated Hospital of Zhejiang University332024-12-032025-02-18
Study of Dalpiciclib Isethionate Plus Pyrotinib Maleate in the Treatment of Advanced Esophageal Squamous Cell Carcinoma
Dalpiciclib + Pyrotinib - Esophageal Squamous Cell Carcinoma
Phase 2RecruitingPeking University352024-11-012024-11-12

Showing 20 of 99. Sign in to see all of them.

Conditions studied

Breast Neoplasms (52)  ·  Carcinoma, Non-Small-Cell Lung (6)  ·  Brain Neoplasms (4)  ·  Breast Diseases (3)  ·  Esophageal Squamous Cell Carcinoma (2)  ·  Triple Negative Breast Neoplasms (2)  ·  Carcinoma, Transitional Cell (1)  ·  Colorectal Neoplasms (1)  ·  Digestive System Neoplasms (1)  ·  Lung Neoplasms (1)  ·  Neoplasm Metastasis (1)  ·  Pathologic Complete Response (1)  ·  Salivary Gland Neoplasms (1)  ·  Stomach Neoplasms (1)

Sponsors

Fudan University (12)  ·  Chinese Academy of Medical Sciences (6)  ·  Henan Cancer Hospital (6)  ·  Sun Yat-sen University (6)  ·  Tianjin Medical University Cancer Institute and Hospital (6)  ·  Cancer Institute and Hospital, Chinese Academy of Medical Sciences (5)  ·  The First Affiliated Hospital with Nanjing Medical University (5)  ·  Shanghai Jiao Tong University School of Medicine (4)  ·  Jiangsu HengRui Medicine Co., Ltd. (3)  ·  Peking Union Medical College Hospital (3)  ·  Second Affiliated Hospital, Zhejiang University, School of Medicine (3)  ·  Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University (3)  ·  Fujian Medical University (2)  ·  Hebei Medical University Fourth Hospital (2)  ·  Peking Union Medical College (2)

Countries

China (78)

Top investigators

Binghe Xu (2)  ·  Min Yan (2)  ·  Xuexin He, MD (2)  ·  Biyun Wang, Chief physician (1)  ·  Caicun Zhou, MD,PhD (1)  ·  Caigang Liu, MD (1)  ·  Chen Xi, PhD (1)  ·  Chunling Jiang (1)  ·  Dingzhi Huang, Doctor (1)  ·  Erwei Song, MD.,Phd. (1)  ·  Fei Ma (1)  ·  Fei Xu, MD (1)  ·  Feilin Cao, Master (1)  ·  Gong Chang, doctor (1)

Results publications

PMID 37296463, PMID 39024777, PMID 28115222, PMID 28498781, PMID 30596880, PMID 31430226, PMID 32614698, PMID 32660609, PMID 32719455, PMID 33328035, PMID 33570247, PMID 34083331, PMID 35085506, PMID 35105939, PMID 35287613, PMID 35321427, PMID 35713517, PMID 35941028, PMID 36135045, PMID 37805496, PMID 38175627, PMID 38290515, PMID 38328709, PMID 38362377, PMID 38469548, PMID 38871705, PMID 39380967, PMID 39425028, PMID 39648226, PMID 40178527, PMID 40743286